CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Edding Genor Group Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Edding Genor Group Holdings Ltd
89 Nexus Way, Camana Bay,
P.O. Box 31106
Phone: +86 2161690700p:+86 2161690700 SHANGHAI, SHA  201203  China Ticker: 69986998
Business Summary
Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in developing and commercialising oncology and autoimmune drugs. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241), Vancocin, Ceclor and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its business in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, President XinNi 54 12/30/2025 12/30/2025
Chief Operation Officer WendeChen 58 7/7/2020 7/7/2020
Senior Vice President - Business Development, Executive Director, Joint Company Secretary JingZhai 42 12/30/2025 12/30/2025
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 17 (As of 6/30/2025)
Outstanding Shares: 528,291,792 (As of 9/30/2025)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 28, 2026